Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A small RCT finds flaxseed oil reduces platelet aggregability but not other risk markers in type 2 diabetes, with no ApoE genotype effect. PICO summary and expert commentary.
An RCT reports topical Wharton's jelly stem cell exosomes dramatically speed diabetic foot ulcer healing, though the control healing time invites caution. PICO summary and expert commentary.
A cluster RCT finds a structured personalised education model markedly improves glycaemic control in type 2 diabetes, though intensity limits generalisability. PICO summary and commentary.
A feasibility analysis finds a culturally tailored dietary intervention engages diverse women with gestational diabetes equally, but does not change measured intake. PICO summary and commentary.
A crossover RCT finds a specific probiotic strain modestly improves fasting glycaemia and beta-cell indices in metformin-treated type 2 diabetes. PICO summary and expert commentary.
A secondary analysis of the BEFORE THE BEGINNING trial finds preconception lifestyle change does not reduce macrosomia or neonatal adiposity. PICO summary and expert commentary.
A pilot RCT finds a culturally tailored WeChat-delivered programme improves self-efficacy and reduces diabetes distress in Chinese Americans with type 2 diabetes. PICO summary and commentary.
A small crossover trial finds a mulberry leaf and corn silk functional milk lowers postprandial glucose only in an overweight prediabetic subgroup. PICO summary and expert commentary.
The Look AHEAD trial demonstrated that intensive lifestyle intervention targeting weight loss in overweight or obese adults with type 2 diabetes did not reduce cardiovascular events over 9.6 years despite clear differences in weight, fitness, and glycaemic control, establishing a critical negative result that informed the rationale for pharmacological obesity treatment with greater weight loss efficacy.
The REWIND trial demonstrated that dulaglutide reduces 3-point MACE in a broad type 2 diabetes population of which 69% had no established cardiovascular disease, with a significant 24% reduction in nonfatal stroke and consistent renal benefit, extending GLP-1 receptor agonist cardiovascular protection into a primary prevention context.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
